FIELD: medicine. SUBSTANCE: material has morphogenetic bone protein and polyoxyethylene-polypropylene-glycol. Polypropylene-glycol molecular mass as ingredient of the polyoxyethylene-polypropylene-glycol is to be taken within the limits from 1500-4000 and ethylene oxide level is to be kept within the limits of 40 to 80% per molecule. Concentration of the polyoxyethylene-polypropylene-glycol is to be equal to 10-50% in aqueous solution. EFFECT: enhanced effectiveness of treatment when locally applying the preparation at the place of bone fracture; high biological affinity to morphogenetic bone protein. 7 cl, 4 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DNA (VARIANTS), METHOD FOR PREPARING PROTEIN, PROTEIN, PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2208638C2 |
| NEW GROWTH/DIFFERENTIATION FACTOR OF TGF-β-FAMILY | 1994 |
|
RU2157406C2 |
| NEW GROWTH/DIFFERENTIATION FACTOR OF TGF-β-FAMILY AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2246315C2 |
| OPTIMISED METHOD OF PURIFYING RECOMBINANT PROTEIN OF GROWTH FACTOR | 2008 |
|
RU2491290C2 |
| BIORESORBABLE WOUND DRESSING | 2012 |
|
RU2577155C2 |
| BONE MATERIAL AND COLLAGEN COMPOSITION FOR RESTORING INJURED ARTICULATIONS | 2001 |
|
RU2292858C2 |
| THERAPEUTIC AGENT FOR SUPPRESSION OF SNORE NOISE | 1999 |
|
RU2243783C2 |
| WATER-SOLUBLE PHARMACEUTICAL COMPOSITION AS IONIC COMPLEX AND ITS USE | 1999 |
|
RU2180855C2 |
| LIPOSOMAL COMPOSITIONS CONTAINING SLIGHTLY ACIDIC DRUGS, AND THEIR USE | 2018 |
|
RU2778886C2 |
| VNS-Met-HISTONES | 2008 |
|
RU2498997C2 |
